Finance

Lists
Outlook: 68.8% bullish·0.0% bearish
Go to analysis
NTRA:NASDAQ
Natera Inc
$399.61
-0.26%
(-1.04) 1D
Oct 7, 1:31:06 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NTRA...
Open
$393.02
High
$400.89
Low
$383.45
Mkt. cap
57.54B
Avg. vol.
1.56M
Volume
1.90M
52-wk high
$437.41
52-wk low
$167.98
EPS
-$1.37
Beta
1.50
Shares outstanding
144.14M
No. of employees
6K
Open
$393.02
High
$400.89
Low
$383.45
Mkt. cap
57.54B
Avg. vol.
1.56M
Volume
1.90M
52-wk high
$437.41
52-wk low
$167.98
EPS
-$1.37
Beta
1.50
Shares outstanding
144.14M
No. of employees
6K
News stories
From web sources and news partners
Profile
Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA testing technology, with a focus on women's health, cancer, and organ health. Natera's proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments in San Carlos, California and Austin, Texas. Wikipedia
About Natera Inc
CEOSteven Chapman
Employees6.14K
FoundedJan 1, 2004
HeadquartersAustin, Texas, United States
SectorBiotechnology
Websitenatera.com
Analyst ratings
Based on 21 analysts giving stock ratings to NTRA in the past 3 months
Strong buy
Buy
20
Hold
1
Sell
0
12-month forecast
Based on 21 Wall Street analysts offering 12 month price targets for NTRA in the last 3 months.
Highest
Current $399.61
$480.00 (+20.12%)
Average
$383.24 (-4.10%)
Lowest
$320.00 (-19.92%)
Analyst
Recommendation
Action
Price target
Projected
Date
Luke Sergott
Barclays
Buy
Maintained
$475.00
+18.9%
10/07/2026
Patrick B Donnelly
Citi
Buy
Maintained
$480.00
+20.1%
10/06/2026
Subbu Nambi
Guggenheim
Buy
Maintained
$475.00
+18.9%
10/01/2026
Eve Burstein
Bernstein
Buy
Maintained
$365.00
-8.7%
09/25/2026
Dan Leonard
RBC Capital
Buy
Maintained
$460.00
+15.1%
09/24/2026
Evie Koslosky
Goldman Sachs
Hold
Maintained
$375.00
-6.2%
09/20/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Maintained
$355.00
-11.2%
09/14/2026
Unknown Analyst
UBS
Buy
Maintained
$435.00
+8.9%
09/09/2026
Doug Schenkel
UBS
Buy
Maintained
$435.00
+8.9%
09/09/2026
Jamie Clark
Rothschild & Co Redburn
Buy
Initiated
$385.00
-3.7%
09/08/2026
David Westenberg
Piper Sandler
Buy
Maintained
$363.50
-9%
08/24/2026
Tycho Peterson
Jefferies
Buy
Maintained
$330.00
-17.4%
08/17/2026
‏Brendan Digan‏
Citi
Buy
Maintained
$365.00
-8.7%
08/14/2026
Unknown Analyst
Stephens
Buy
Maintained
$350.00
-12.4%
08/12/2026
Matt Larew
William Blair
Buy
Reiterated
-
-
08/07/2026
Daniel Markowitz CFA
Evercore ISI
Buy
Maintained
$360.00
-9.9%
08/07/2026
Catherine Ramsey Schulte
Robert W. Baird
Buy
Maintained
$348.00
-12.9%
08/07/2026
Kyle Mikson CFA
Canaccord Genuity
Buy
Maintained
$375.00
-6.2%
08/07/2026
Brandon Couillard
Wells Fargo
Hold
Maintained
$284.00
-28.9%
08/07/2026
Casey Woodring
J.P. Morgan
Buy
Reiterated
$360.00
-9.9%
08/07/2026
Mark Massaro
BTIG
Buy
Reiterated
$320.00
-19.9%
08/07/2026
Puneet Souda
Leerink Partners
Buy
Maintained
$330.00
-17.4%
08/07/2026
Daniel Brennan
TD Cowen
Buy
Reiterated
$340.00
-14.9%
08/07/2026
William Bonello
Craig-Hallum
Buy
Maintained
-
-
07/09/2026
Paige Chamberlain‏
Wolfe Research
Buy
Reiterated
$260.00
-34.9%
06/01/2026
Unknown Analyst
Wolfe Research
Buy
Reiterated
$260.00
-34.9%
06/01/2026
Andrew Brackmann
William Blair
Buy
Maintained
-
-
05/08/2026
Unknown Analyst
Jefferies
Buy
Reiterated
$275.00
-31.2%
02/27/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
-$0.47 / -$0.53
+11.99%beat
Revenue / Est. (USD)
752.75M / 661.29M
+13.83%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
592.18M
665.50M
696.64M
752.75M
Cost of goods sold
207.80M
220.07M
245.81M
267.56M
Cost of revenue
207.80M
220.07M
245.81M
267.56M
Research and development expenses
173.41M
175.19M
210.70M
228.07M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
308.55M
291.30M
320.74M
328.87M
Operating expense
481.96M
468.21M
537.15M
562.65M
Total operating expenses
689.76M
688.28M
782.96M
830.21M
Operating income
-97.58M
-22.78M
-86.32M
-77.46M
Other non operating income
-
-
-
-
EBT including unusual items
-87.34M
-13.33M
-84.81M
-67.23M
EBT excluding unusual items
-87.34M
-13.33M
-77.61M
-68.90M
Income tax expense
207.00K
-60.58M
283.00K
-261.00K
Effective tax rate
-0.24%
454.63%
-0.33%
0.39%
Other operating expenses
-
-
-
-
Net income
-87.54M
47.26M
-85.09M
-66.97M
Net profit margin
-14.78%
7.10%
-12.21%
-8.90%
Earnings per share
-0.64
0.36
-0.60
-0.47
Interest and investment income
11.28M
10.45M
9.60M
9.45M
Interest expense
-1.04M
-991.00K
-892.00K
-890.00K
Net interest expenses
10.24M
9.46M
8.71M
8.56M
Depreciation and amortization charges
-
-
-
-
EBITDA
-87.28M
-13.69M
-66.09M
-56.27M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps